SPOTLIGHT: ASCO to weigh in on cancer drug costs


As chemotherapy prices leap by 15 percent per year--and with some equally effective meds priced thousands apart--oncologists will soon get guidelines from their professional society for talking to patients about the cost of cancer treatment. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.